Albert Ming Yu, MD
Pediatrics · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Yu’s office at (650) 497-8000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A98552 · Current
Licensed to practise in California · since 2007 · expires 2027-01-31 · University of California, Los Angeles School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Pediatrics - Pediatrics
Medicaid work
$22,097 in 2024
Medicaid paid $22,097 for 850 billed services this clinician did in 2024, up to 52 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Developmental screening | 153 | $7,130 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B | 108 | $6,691 |
| Return visit (30+ min) | 474 | $2,871 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 17 | $1,864 |
| Screening test, pure tone, air only | 73 | $1,618 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 13 | $1,051 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 12 | $873 |
| 2024 | 850 | 7 | 52 | $22,097 |
| 2023 | 867 | 10 | 57 | $15,691 |
| 2022 | 1,197 | 9 | 56 | $7,569 |
| 2021 | 1,809 | 12 | 43 | $3,380 |
| 2020 | 1,423 | 13 | 69 | $2,115 |
| 2019 | 1,847 | 11 | 53 | $2,839 |
| 2018 | 2,394 | 13 | 77 | $0 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 555 | $3,243 |
| Developmental screening | 62 | $2,841 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) | 51 | $2,110 |
| SARSCOV CORONAVIRUS AG IA | 54 | $1,936 |
| Screening test, pure tone, air only | 74 | $1,636 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 13 | $1,425 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B | 20 | $1,284 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 12 | $873 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 12 | $225 |
| Short return visit (20+ min) | 14 | $118 |
2022
| Return visit (30+ min) | 469 | $3,275 |
| Short return visit (20+ min) | 151 | $1,752 |
| Screening test, pure tone, air only | 189 | $1,290 |
| Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered | 98 | $497 |
| Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure) | 44 | $350 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 33 | $175 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 58 | $159 |
| Bilateral quantitative screening test of visual acuity | 141 | $72 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 14 | $0 |
2021
| Return visit (30+ min) | 302 | $1,024 |
| Short return visit (20+ min) | 182 | $880 |
| Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered | 276 | $630 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 24 | $306 |
| Screening test, pure tone, air only | 319 | $200 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 73 | $115 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 88 | $82 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 97 | $55 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 26 | $40 |
| Bilateral quantitative screening test of visual acuity | 313 | $34 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 39 | $14 |
| Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure) | 70 | $0 |
2020
| Return visit (30+ min) | 279 | $1,185 |
| Short return visit (20+ min) | 78 | $428 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 38 | $165 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 39 | $132 |
| Screening test, pure tone, air only | 208 | $100 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Influenza | 64 | $53 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 134 | $52 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Streptococcus, group A | 18 | $0 |
| Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered | 212 | $0 |
| Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure) | 65 | $0 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 73 | $0 |
| Bilateral quantitative screening test of visual acuity | 187 | $0 |
2019
| Return visit (30+ min) | 429 | $1,644 |
| Short return visit (20+ min) | 220 | $817 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 81 | $231 |
| Screening test, pure tone, air only | 280 | $83 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 87 | $35 |
| Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered | 311 | $22 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 41 | $7 |
| Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure) | 57 | $0 |
| Bilateral quantitative screening test of visual acuity | 259 | $0 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 24 | $0 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 58 | $0 |
2018
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Influenza | 66 | $0 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Streptococcus, group A | 27 | $0 |
| Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered | 362 | $0 |
| Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure) | 65 | $0 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 83 | $0 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 140 | $0 |
| Screening test, pure tone, air only | 285 | $0 |
| Bilateral quantitative screening test of visual acuity | 265 | $0 |
| Short return visit (20+ min) | 318 | $0 |
| Return visit (30+ min) | 540 | $0 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 65 | $0 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 70 | $0 |
Money from drug and device companies
$32 in 2023
A payment is not proof that care is biased.
| Sanofi-Aventis U.S. | Tzield | $32 | 1 payment
|
See the published payment
| Sanofi-Aventis U.S. | Meals · 2023-09-07 | Tzield | $32 |
Professional record
- NPI
- 1982922340
- Licence
- CA A98552California A98552: Current · expires 2027-01-31
More record details
- Sole proprietor
- No
- Taxonomy
- Pediatrics (208000000X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2010-05-11
- NPI last updated
- 2023-04-04
- NPI record certified
- 2023-04-04
This is when the NPI record was last certified, not a medical board exam.